Celgene to present new blood cancer, solid tumor clinical data at ASCO

Celgene announced that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating Celgene agents will be presented at the American Society of Clinical Oncology Annual Meeting between June 1-5 in Chicago, Ill. In blood cancers, abstracts continue to support the role of Celgene’s IMiD therapies as a foundation of multiple myeloma research. Multiple studies highlighting key Celgene research collaborations of investigational compounds will also be presented, including updated data from the first clinical study of anti-BCMA CAR T therapy bb2121 in multiple myeloma. In addition, results of the study evaluating the investigational R2 regimen REVLIMID and rituximab combination) as first-line therapy in previously-untreated follicular lymphoma patients will also be presented. Experts will also share results from a study of JCAR017, an investigational CAR T cell therapy, in relapsed/refractory aggressive b-cell non-Hodgkin’s lymphoma. In solid tumors, data evaluating the investigational combination of atezolizumab with ABRAXANE + carboplatin will offer a first look at the clinical profile of an immunotherapy/chemotherapy combination in advanced squamous non-small cell lung cancer patients

https://bit.ly/2Is3eHI